Development of orphan vaccines: An industry perspective

Emerging Infectious Diseases

Volumn 5, Issue 6, 1999, Pages 749-756

  Lang, Jean ^a,b   Wood, Susan C ^a  

^a Pasteur Merieux Connaught (PMC)   (France)

^b Vec Borne Diseases Clinical Program   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG; ORPHAN VACCINE; UNCLASSIFIED DRUG; VACCINE;

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; INFECTION; LAW; REVIEW; VACCINE PRODUCTION;

EID: 0033400404     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0506.990602     Document Type: Review

References (30)

1. Dodet B, Saluzzo J. Factor in the emergence of arbovirus diseases. (Les Pensières): Veyrier du Lac Elsevier Science 1997; 8-10 Decembre 1996.
2. Brealey RA, Myers SC. In: Principles of corporate finance. 3rd ed. Singapore: McGraw-Hill; 1988.
3. Stucki J. The development of orphan drugs - a pharmaceutical company perspective. Cooperative approaches to research and development of orphan drugs 1985;95-104.
4. Aylward B, Kane M, Batson A, Scott R. A framework for the evaluation of vaccines for use in expanded programme on immunization. Vaccine 1994;12:1155-9.
5. Shepard DS, Walsh JA, Kleinau E, Stansfield S, Bhalotra S. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 1995;13:707-14.
6. Milstien J, Batson A. Accelerating availability of new vaccines: the role of the international community. Drug Inf J 1998;32:175-82.
7. CVI (Children's vaccine initiative). The CVI strategic plan - managing opportunity and change: a vision of vaccination for the 21st century. OMS 1997;CVI/ GEN(97-04):1-92.
8. Trannoy E. Will ethical and liability issues and public acceptance allow maternal immunization? Vaccine 1998;16:1482-5.
9. Haffner M. Orphan products: origins, progress, and prospects. Annu Rev Pharmacol Toxicol 1991;31:603-20.
10. Haffner M, Kelsey J. Evaluation of orphan products by the U.S. Food and Drug Administration. Int J Tech Assess Health Care 1992;8:647-57.
11. Cramer R. Orphan drugs improved medical treatment of rare diseases. Alabama J Med Sci 1998;25:257-67.
12. Thamer M, Brennan N, Semansky R. A cross-national comparison of orphan drug policies: implications for the U.S. Orphan Drug Act. J Health Pol Policy Law 1998;23:265-90.
13. Scharf S. Orphan drugs: the question of product liability. Am J Law Med 1985;10:491-513.
14. Bloom B. The United States needs a national vaccine authority. Science 1994;265:1378-80.
15. Brandissou S, Yagoubi N, Hasselot N. Les médicaments orphelins: problème de santé publique et enjeux économiques. Thérapie 1996;51:647-53.
16. Benzi G, Ceci A. Drugs trying to get the patents: there will be incentives for the European scientific community to develop research in the field of the orphan drugs. Pharmacol Res 1997;35:89-93.
17. Hillcoat BL. Rare diseases and "orphan" drugs [editorial]. Med J Aust 1998;169:69-70.
18. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 1999;17:646-52.
19. Local initiative aids in fight against malaria [editorial]. Lancet 1998;352:212.
20. Ollario P. Will the fight against tropical diseases benefit from orphan drug status? Trop Med Int Health 1997;2:113-5.
21. Muraskin W. The politics of international health: the children's vaccine initiative and the struggle to develop vaccines for the third world. Albany (NY): State University of New York Press; 1998.
22. Milstien J, Batson A, Meaney W. A systematic method for evaluation of the potential viability of local vaccine producers. Vaccine 1997;15:1358-63.
23. Batson A. Sustainable introduction of affordable new vaccines: the targeting strategy. Vaccine 1998;16:S93-8.
24. Bloom B. Bumps on the vaccine road. Science 1994;265:1371-3.
25. Hausdorff WP. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine 1996;14:1179-86.
26. Public-private partnerships - business as usual [editorial]. Lancet 1998;352:212.
27. Spier R. Report on a meeting of a working party sponsored by the European Commission to discuss the ethical, legal and social aspects of research on vaccines and vaccination. Vaccine 1999;17:400-2.
28. Maiztegui J, MacKee K, Barrera Oro J, Harrison L, Gibbs P, Feuillade M, et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 1998;177:277-83.
29. Helenport J, Roche G. What have been the strategies for the registration, positioning and control of medical information for im artemether? The rational use of Qinghaosu and its derivatives. 1998; Les Pensières (19-22 April):141-7, Fondation Merieux Eds.
30. Beutels P. Economic evaluations applied to HB vaccination: general observations. Vaccine 1998;16:S84-92.